Britta Lamottke

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma

Ulrike Heider, Jessica Rademacher, Britta Lamottke et al. · European Journal Of Haematology · 2009 · 172 citations

Proteasome Inhibitors, Chemoprevention Strategy, Immunology +19

A novel germline POLE mutation causes an early onset cancer prone syndrome mimicking constitutional mismatch repair deficiency

Katharina Wimmer, Andreas Beilken, R. Nustede et al. · Familial Cancer · 2016 · 74 citations · Full text

Genome Instability, Somatic Variant, Genetic Disorder +7

Serum concentrations of DKK‐1 decrease in patients with multiple myeloma responding to anti‐myeloma treatment

Ulrike Heider, Martin Kaiser, Maren Mieth et al. · European Journal Of Haematology · 2008 · 69 citations · Full text

Synergistic action of the novel HSP90 inhibitor NVP‐AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma

Martin Kaiser, Britta Lamottke, Maren Mieth et al. · European Journal Of Haematology · 2009 · 44 citations

Hematological Malignancy, Tumor Biology, Sequential Incubation +13

Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors

Agnes Bonifacius, Britta Lamottke, Sabine Tischer‐Zimmermann et al. · Journal of Clinical Investigation · 2023 · 33 citations · Full text

Cell Therapy, Immunology, Transplantation Medicine +16